Primary results of a randomized two‐by‐two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S‐1 and docetaxel/cisplatin/S‐1 as neoadjuvant chemotherapy for advanced gastric cancer
Abstract Aim Neoadjuvant chemotherapy (NAC) is promising to improve the survival of resectable gastric cancer. However, suitable regimen and treatment duration for NAC have not yet been established. Methods We conducted a randomized phase II trial to compare two and four courses of neoadjuvant S‐1/c...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-09-01
|
| Series: | Annals of Gastroenterological Surgery |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ags3.12352 |
| _version_ | 1818337847039492096 |
|---|---|
| author | Tsutomu Hayashi Takaki Yoshikawa Kentaro Sakamaki Kazuhiro Nishikawa Kazumasa Fujitani Kazuaki Tanabe Kazunari Misawa Takanori Matsui Akira Miki Hiroshi Nemoto Tetsu Fukunaga Yutaka Kimura Jun Hihara |
| author_facet | Tsutomu Hayashi Takaki Yoshikawa Kentaro Sakamaki Kazuhiro Nishikawa Kazumasa Fujitani Kazuaki Tanabe Kazunari Misawa Takanori Matsui Akira Miki Hiroshi Nemoto Tetsu Fukunaga Yutaka Kimura Jun Hihara |
| author_sort | Tsutomu Hayashi |
| collection | DOAJ |
| description | Abstract Aim Neoadjuvant chemotherapy (NAC) is promising to improve the survival of resectable gastric cancer. However, suitable regimen and treatment duration for NAC have not yet been established. Methods We conducted a randomized phase II trial to compare two and four courses of neoadjuvant S‐1/cisplatin (SC) and S‐1/cisplatin/docetaxel(DCS) using a two‐by‐two factorial design for locally resectable advanced gastric cancer. Patients with M0 and either T4 or T3 in case of junctional cancer or scirrhous‐type cancer received two or four courses of SC or DCS. Then, patients underwent D2 gastrectomy and adjuvant S‐1 chemotherapy for 1 year. The primary endpoint was 3‐year overall survival. The planned sample size was 120 eligible patients. Results Between October 2011 and September 2014, 132 patients were assigned to CS (n = 66; 33 in 2‐courses and 33 in 4‐courses) and DCS (n = 66; 33 in 2‐courses and 33 in 4‐courses). The 3‐year OS was 58.1% in CS and 60.0% in DCS with hazard ratio of 0.80 (95% CI, 0.48‐1.34), while it was 53.1% in the two courses and 65.0% in the four courses with hazard ratio of 0.72 (95% CI, 0.43‐1.22). In the survival analysis by duration in each regimen, the 3‐year OS was 58.1% for both two and four courses in CS, while it was 48.5% for two courses of DCS and 71.9% for four courses of DCS. Conclusions Considering high 3‐year OS, four courses DCS has a value to be tested in a future phase III study to confirm superiority of neoadjuvant chemotherapy for locally advanced gastric cancer. |
| first_indexed | 2024-12-13T15:01:43Z |
| format | Article |
| id | doaj.art-f9e2aa86ef2344ac9777405e4e4ee24b |
| institution | Directory Open Access Journal |
| issn | 2475-0328 |
| language | English |
| last_indexed | 2024-12-13T15:01:43Z |
| publishDate | 2020-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | Annals of Gastroenterological Surgery |
| spelling | doaj.art-f9e2aa86ef2344ac9777405e4e4ee24b2022-12-21T23:41:07ZengWileyAnnals of Gastroenterological Surgery2475-03282020-09-014554054810.1002/ags3.12352Primary results of a randomized two‐by‐two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S‐1 and docetaxel/cisplatin/S‐1 as neoadjuvant chemotherapy for advanced gastric cancerTsutomu Hayashi0Takaki Yoshikawa1Kentaro Sakamaki2Kazuhiro Nishikawa3Kazumasa Fujitani4Kazuaki Tanabe5Kazunari Misawa6Takanori Matsui7Akira Miki8Hiroshi Nemoto9Tetsu Fukunaga10Yutaka Kimura11Jun Hihara12Gastric Surgery National Cancer Center Hospital Chuo‐ku JapanGastric Surgery National Cancer Center Hospital Chuo‐ku JapanCenter for Data Science Yokohama City University Yokohama JapanNational Hospital Organization Osaka National Hospital Osaka JapanOsaka General Medical Center Osaka JapanGraduate School Hiroshima University Hiroshima JapanAichi Cancer Center Hospital Nagoya JapanAichi Cancer Center Aichi Hospital Nagoya JapanKobe City Medical Center General Hospital Kobe JapanFujigaoka Hospital Showa University Yokohama JapanUniversity Hospital St. Marianna University School of Medicine Kawasaki City JapanSakai City Medical Center Sakai JapanHiroshima City Asa Hospital Hiroshima JapanAbstract Aim Neoadjuvant chemotherapy (NAC) is promising to improve the survival of resectable gastric cancer. However, suitable regimen and treatment duration for NAC have not yet been established. Methods We conducted a randomized phase II trial to compare two and four courses of neoadjuvant S‐1/cisplatin (SC) and S‐1/cisplatin/docetaxel(DCS) using a two‐by‐two factorial design for locally resectable advanced gastric cancer. Patients with M0 and either T4 or T3 in case of junctional cancer or scirrhous‐type cancer received two or four courses of SC or DCS. Then, patients underwent D2 gastrectomy and adjuvant S‐1 chemotherapy for 1 year. The primary endpoint was 3‐year overall survival. The planned sample size was 120 eligible patients. Results Between October 2011 and September 2014, 132 patients were assigned to CS (n = 66; 33 in 2‐courses and 33 in 4‐courses) and DCS (n = 66; 33 in 2‐courses and 33 in 4‐courses). The 3‐year OS was 58.1% in CS and 60.0% in DCS with hazard ratio of 0.80 (95% CI, 0.48‐1.34), while it was 53.1% in the two courses and 65.0% in the four courses with hazard ratio of 0.72 (95% CI, 0.43‐1.22). In the survival analysis by duration in each regimen, the 3‐year OS was 58.1% for both two and four courses in CS, while it was 48.5% for two courses of DCS and 71.9% for four courses of DCS. Conclusions Considering high 3‐year OS, four courses DCS has a value to be tested in a future phase III study to confirm superiority of neoadjuvant chemotherapy for locally advanced gastric cancer.https://doi.org/10.1002/ags3.12352cisplatin/S‐1docetaxel/cisplatin/S‐1gastric cancerneoadjuvant therapy |
| spellingShingle | Tsutomu Hayashi Takaki Yoshikawa Kentaro Sakamaki Kazuhiro Nishikawa Kazumasa Fujitani Kazuaki Tanabe Kazunari Misawa Takanori Matsui Akira Miki Hiroshi Nemoto Tetsu Fukunaga Yutaka Kimura Jun Hihara Primary results of a randomized two‐by‐two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S‐1 and docetaxel/cisplatin/S‐1 as neoadjuvant chemotherapy for advanced gastric cancer Annals of Gastroenterological Surgery cisplatin/S‐1 docetaxel/cisplatin/S‐1 gastric cancer neoadjuvant therapy |
| title | Primary results of a randomized two‐by‐two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S‐1 and docetaxel/cisplatin/S‐1 as neoadjuvant chemotherapy for advanced gastric cancer |
| title_full | Primary results of a randomized two‐by‐two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S‐1 and docetaxel/cisplatin/S‐1 as neoadjuvant chemotherapy for advanced gastric cancer |
| title_fullStr | Primary results of a randomized two‐by‐two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S‐1 and docetaxel/cisplatin/S‐1 as neoadjuvant chemotherapy for advanced gastric cancer |
| title_full_unstemmed | Primary results of a randomized two‐by‐two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S‐1 and docetaxel/cisplatin/S‐1 as neoadjuvant chemotherapy for advanced gastric cancer |
| title_short | Primary results of a randomized two‐by‐two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S‐1 and docetaxel/cisplatin/S‐1 as neoadjuvant chemotherapy for advanced gastric cancer |
| title_sort | primary results of a randomized two by two factorial phase ii trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin s 1 and docetaxel cisplatin s 1 as neoadjuvant chemotherapy for advanced gastric cancer |
| topic | cisplatin/S‐1 docetaxel/cisplatin/S‐1 gastric cancer neoadjuvant therapy |
| url | https://doi.org/10.1002/ags3.12352 |
| work_keys_str_mv | AT tsutomuhayashi primaryresultsofarandomizedtwobytwofactorialphaseiitrialcomparingneoadjuvantchemotherapywithtwoandfourcoursesofcisplatins1anddocetaxelcisplatins1asneoadjuvantchemotherapyforadvancedgastriccancer AT takakiyoshikawa primaryresultsofarandomizedtwobytwofactorialphaseiitrialcomparingneoadjuvantchemotherapywithtwoandfourcoursesofcisplatins1anddocetaxelcisplatins1asneoadjuvantchemotherapyforadvancedgastriccancer AT kentarosakamaki primaryresultsofarandomizedtwobytwofactorialphaseiitrialcomparingneoadjuvantchemotherapywithtwoandfourcoursesofcisplatins1anddocetaxelcisplatins1asneoadjuvantchemotherapyforadvancedgastriccancer AT kazuhironishikawa primaryresultsofarandomizedtwobytwofactorialphaseiitrialcomparingneoadjuvantchemotherapywithtwoandfourcoursesofcisplatins1anddocetaxelcisplatins1asneoadjuvantchemotherapyforadvancedgastriccancer AT kazumasafujitani primaryresultsofarandomizedtwobytwofactorialphaseiitrialcomparingneoadjuvantchemotherapywithtwoandfourcoursesofcisplatins1anddocetaxelcisplatins1asneoadjuvantchemotherapyforadvancedgastriccancer AT kazuakitanabe primaryresultsofarandomizedtwobytwofactorialphaseiitrialcomparingneoadjuvantchemotherapywithtwoandfourcoursesofcisplatins1anddocetaxelcisplatins1asneoadjuvantchemotherapyforadvancedgastriccancer AT kazunarimisawa primaryresultsofarandomizedtwobytwofactorialphaseiitrialcomparingneoadjuvantchemotherapywithtwoandfourcoursesofcisplatins1anddocetaxelcisplatins1asneoadjuvantchemotherapyforadvancedgastriccancer AT takanorimatsui primaryresultsofarandomizedtwobytwofactorialphaseiitrialcomparingneoadjuvantchemotherapywithtwoandfourcoursesofcisplatins1anddocetaxelcisplatins1asneoadjuvantchemotherapyforadvancedgastriccancer AT akiramiki primaryresultsofarandomizedtwobytwofactorialphaseiitrialcomparingneoadjuvantchemotherapywithtwoandfourcoursesofcisplatins1anddocetaxelcisplatins1asneoadjuvantchemotherapyforadvancedgastriccancer AT hiroshinemoto primaryresultsofarandomizedtwobytwofactorialphaseiitrialcomparingneoadjuvantchemotherapywithtwoandfourcoursesofcisplatins1anddocetaxelcisplatins1asneoadjuvantchemotherapyforadvancedgastriccancer AT tetsufukunaga primaryresultsofarandomizedtwobytwofactorialphaseiitrialcomparingneoadjuvantchemotherapywithtwoandfourcoursesofcisplatins1anddocetaxelcisplatins1asneoadjuvantchemotherapyforadvancedgastriccancer AT yutakakimura primaryresultsofarandomizedtwobytwofactorialphaseiitrialcomparingneoadjuvantchemotherapywithtwoandfourcoursesofcisplatins1anddocetaxelcisplatins1asneoadjuvantchemotherapyforadvancedgastriccancer AT junhihara primaryresultsofarandomizedtwobytwofactorialphaseiitrialcomparingneoadjuvantchemotherapywithtwoandfourcoursesofcisplatins1anddocetaxelcisplatins1asneoadjuvantchemotherapyforadvancedgastriccancer |